Metabolic syndrome historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(13 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Metabolic syndrome}}
{{Metabolic syndrome}}
 
{{CMG}}; {{AE}} [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com] ; {{ADG}}
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh@perfuse.org]


==Overview==
==Overview==
'''Metabolic syndrome''' is a combination of [[medicine|medical]] disorders that increase one's risk for [[cardiovascular disease]] and [[Diabetes mellitus|diabetes]]. It affects a large number of people in a clustered fashion. In some studies, the [[prevalence]] in the USA is calculated as being up to 25% of the population.
The term "metabolic syndrome" dates back to at least the late 1950s, but came into common usage in the late 1970s to describe various associations of risk factors with [[Diabetes mellitus|diabetes]]. In 1977, Haller coined the term "metabolic syndrome" for the first time when describing the additive effects of risk factors on [[atherosclerosis]].


==Historical Perspective==
==Historical Perspective==
The term "metabolic syndrome" dates back to at least the late 1950s, but came into common usage in the late 1970s to describe various associations of risk factors with diabetes, that had been noted as early as the 1920s.<ref>Joslin EP. The prevention of diabetes mellitus. ''JAMA'' 1921;76:79–84.</ref><ref>Kylin E. [Studies of the hypertension-hyperglycemia-hyperuricemia syndrome] (German). ''Zentralbl Inn Med'' 1923;44: 105-27.</ref>
*The term "metabolic syndrome" dates back to at least the late 1950s, but came into common usage in the late 1970s to describe various associations of [[risk factors]] with [[diabetes]].<ref>Joslin EP. The prevention of diabetes mellitus. ''JAMA'' 1921;76:79–84.</ref><ref>Kylin E. [Studies of the hypertension-hyperglycemia-hyperuricemia syndrome] (German). ''Zentralbl Inn Med'' 1923;44: 105-27.</ref>
* The Marseilles physician Dr. Jean Vague, in 1947, made the interesting observation that upper body obesity appeared to predispose to diabetes, atherosclerosis, gout, and calculi.<ref>Vague J. La diffférenciacion sexuelle, facteur déterminant des formes de l'obésité. Presse Med 1947;30:339-40.</ref>  
*In 1947, Dr. Jean Vague proposed a theory that upper body [[obesity]] predisposed to [[diabetes]], [[atherosclerosis]], [[gout]], and [[calculi]].<ref>Vague J. La diffférenciacion sexuelle, facteur déterminant des formes de l'obésité. Presse Med 1947;30:339-40.</ref>  
* Avogaro, Crepaldi and co-workers described six moderately obese patients with diabetes, hypercholesterolemia, and marked hypertriglyceridemia all of which improved when the patients were put on a hypocaloric, low carbohydrate diet.<ref>Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. ''Acta Diabetol Lat'' 1967;4:572-590.</ref>
*In 1967, Avogaro, Crepaldi and co-workers discovered obese patients with [[diabetes]], [[hypercholesterolemia]], and marked [[hypertriglyceridemia]] improved when they were put on a hypocaloric, low [[carbohydrate]] diet.<ref>Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. ''Acta Diabetol Lat'' 1967;4:572-590.</ref>
* In 1977, Haller used the term "metabolic syndrome" for associations of obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia and steatosis hepatis when describing the additive effects of risk factors on atherosclerosis.<ref>Haller H. [Epidemiology and associated risk factors of hyperlipoproteinemia] (German). ''Z Gesamte Inn Med'' 1977;32(8):124-8. PMID 883354.</ref>
*In 1977, Haller coined the term "metabolic syndrome" for the first time when describing the additive effects of [[risk factors]] on [[atherosclerosis]].<ref>Haller H. [Epidemiology and associated risk factors of hyperlipoproteinemia] (German). ''Z Gesamte Inn Med'' 1977;32(8):124-8. PMID 883354.</ref>
* The same year, Singer used the term for associations of obesity, gout, diabetes mellitus, and hypertension with hyperlipoprotenemia.<ref>Singer P. [Diagnosis of primary hyperlipoproteinemias] (German). ''Z Gesamte Inn Med'' 1977;32(9):129-33. PMID 906591.</ref>
*In 1977, Singer coined the term [[hyperlipoproteinemia]] to describe the associations of [[obesity]], [[gout]], [[diabetes mellitus]], and [[hypertension]] with metabolic syndrome.<ref>Singer P. [Diagnosis of primary hyperlipoproteinemias] (German). ''Z Gesamte Inn Med'' 1977;32(9):129-33. PMID 906591.</ref>
* In 1977 and 1978, Gerald B. Phillips developed the concept that risk factors for myocardial infarction concur to form a "constellation of abnormalities" (i.e., glucose intolerance, hyperinsulinemia, hyperlipidemia [hypercholesterolemia and hypertriglyceridemia] and hypertension) that is associated not only with heart disease, but also with aging, obesity and other clinical states. He suggested there must be an underlying linking factor, the identification of which could lead to the prevention of cardiovascular disease; he hypothesized that this factor was sex hormones.<ref>Phillips GB. Sex hormones, risk factors and cardiovascular disease. ''Am J Med'' 1978;65:7-11. PMID 356599.</ref><ref>Phillips GB. Relationship between serum sex hormones and glucose, insulin, and lipid abnormalities in men with myocardial infarction. ''Proc Natl Acad Sci U S A'' 1977;74:1729-1733. PMID 193114.</ref>
*In 1977 and 1978, Gerald B. Phillips developed the concept that [[risk factors]] for [[myocardial infarction]] are not only associated with [[heart]] disease, but also with [[aging]], [[obesity]] and other clinical states.<ref>Phillips GB. Sex hormones, risk factors and cardiovascular disease. ''Am J Med'' 1978;65:7-11. PMID 356599.</ref><ref>Phillips GB. Relationship between serum sex hormones and glucose, insulin, and lipid abnormalities in men with myocardial infarction. ''Proc Natl Acad Sci U S A'' 1977;74:1729-1733. PMID 193114.</ref>
* In 1988, in his Banting lecture, Gerald M. Reaven proposed insulin resistance as the underlying factor and named the constellation of abnormalities Syndrome X. Reaven did not include abdominal obesity, which has also been hypothesized as the underlying factor, as part of the condition.<ref>Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. PMID 3056758.</ref>
*In 1988, Gerald M. Reaven proposed [[insulin resistance]] as the underlying factor and named the constellation of abnormalities as [[Syndrome X]].<ref>Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. PMID 3056758.</ref>
 
The terms "metabolic syndrome," "insulin resistance syndrome," and "syndrome X" are now used specifically to define a constellation of abnormalities that is associated with increased risk for the development of type 2 diabetes and atherosclerotic vascular disease (e.g. heart disease and stroke).
 
 
==Related Chapters==
* [[Hyperinsulinemia]]
* [[Insulin resistance]]
* [[Chronic Somogyi rebound]]


==References==
==References==
Line 31: Line 22:
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Endocrinology]]
[[Category:Endocrinology]]
[[Category:Genetic disorders]]
[[Category:Metabolic disorders]]
[[Category:Rheumatology]]
[[Category:Rheumatology]]
[[Category:Overview complete]]
[[Category:Template complete]]
[[Category:Medical conditions related to obesity]]
[[Category:Syndromes]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]

Latest revision as of 14:30, 16 October 2017

Metabolic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Metabolic Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Dietary Therapy

Physical Activity

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Metabolic syndrome historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Metabolic syndrome historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Metabolic syndrome historical perspective

CDC on Metabolic syndrome historical perspective

Metabolic syndrome historical perspective in the news

Blogs on Metabolic syndrome historical perspective

Directions to Hospitals Treating Metabolic syndrome

Risk calculators and risk factors for Metabolic syndrome historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, M.B.B.S. [2] ; Aditya Ganti M.B.B.S. [3]

Overview

The term "metabolic syndrome" dates back to at least the late 1950s, but came into common usage in the late 1970s to describe various associations of risk factors with diabetes. In 1977, Haller coined the term "metabolic syndrome" for the first time when describing the additive effects of risk factors on atherosclerosis.

Historical Perspective

References

  1. Joslin EP. The prevention of diabetes mellitus. JAMA 1921;76:79–84.
  2. Kylin E. [Studies of the hypertension-hyperglycemia-hyperuricemia syndrome] (German). Zentralbl Inn Med 1923;44: 105-27.
  3. Vague J. La diffférenciacion sexuelle, facteur déterminant des formes de l'obésité. Presse Med 1947;30:339-40.
  4. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat 1967;4:572-590.
  5. Haller H. [Epidemiology and associated risk factors of hyperlipoproteinemia] (German). Z Gesamte Inn Med 1977;32(8):124-8. PMID 883354.
  6. Singer P. [Diagnosis of primary hyperlipoproteinemias] (German). Z Gesamte Inn Med 1977;32(9):129-33. PMID 906591.
  7. Phillips GB. Sex hormones, risk factors and cardiovascular disease. Am J Med 1978;65:7-11. PMID 356599.
  8. Phillips GB. Relationship between serum sex hormones and glucose, insulin, and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci U S A 1977;74:1729-1733. PMID 193114.
  9. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. PMID 3056758.

Template:WS Template:WH